Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 20/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 18/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | PPARD | Q03181 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994166 | 0.98 | NR1H2 (0.53) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL994844 | 0.97 | NR1H2 (0.52) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL2352976 | 0.97 | NR1H2 (0.51) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL3171339 | 0.95 | NR1H2 (0.50) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL994812 | 0.94 | NR1H2 (0.51) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL994749 | 0.92 | NR1H2 (0.49) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL994765 | 0.92 | NR1H2 (0.53) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL12392158 | 0.92 | NR1H2 (0.43) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL2346614 | 0.91 | NR1H2 (0.49) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL995748 | 0.91 | NR1H2 (0.49) | NR1H2NR1H3PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2023-10-26 | — | — | US | disclosed |
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | THE ROCKEFELLER UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-20190125745-A1 | TREATMENT AND DIAGNOSIS OF CANCER | RGENIX, INC. | 2019-05-02 | — | — | US | disclosed |
| US-20190029984-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2019-01-31 | — | — | US | disclosed |
| WO-2018222975-A1 | METHODS FOR THE TREATMENT OF CANCER | RGENIX, INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| EP-3402477-A2 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | The Rockefeller University (US) | 2018-11-21 | — | — | EP | disclosed |
| WO-2017123568-A2 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2017-07-20 | — | — | WO | disclosed |
| WO-2016100619-A2 | TREATMENT AND DIAGNOSIS OF CANCER | RGENIX, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-8008306-B2 | Quinoline compounds | KOWA COMPANY, LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| EP-2272843-A1 | QUINOLINE COMPOUND | Kowa Company, Ltd. (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20100016327-A1 | QUINOLINE COMPOUNDS | KOWA COMPANY, LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | NR1H3, NR1H2, MCL1 | NR1H2 2/4885NR1H3 1/4885PPARG 131/4885 |
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | NR1H3, NR1H2, MCL1 | NR1H2 2/4885NR1H3 1/4885PPARG 131/4885 |
| US-20190029984-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | NR1H3, NR1H2, MCL1 | NR1H2 2/4885NR1H3 1/4885PPARG 131/4885 |
| US-20190125745-A1 | TREATMENT AND DIAGNOSIS OF CANCER | NR1H4, NR1H3, NR1H2 | NR1H2 3/4885NR1H3 2/4885PPARG 89/4885 |
| US-20100016327-A1 | QUINOLINE COMPOUNDS | NR1H2, NR1H3, LDLR | NR1H2 1/4885NR1H3 2/4885PPARG 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.